2017-07-25T07:21:42-05:00 2016-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2016-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 LOUIS D SCHWARTZ CFO 2128471111 2017-07-25 1 3019519090 75.103.231.202 2017-07-25 08:20:50 ED P 24E2B1EDDFB7997E904F8C8AA54720A5F314F67A C5EF97B7BDE0E637AB26D20CD76004D479A0609A 2016 2021-01-29 14:40:06Z MARK FEINBERG 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 91210270 0 X WWW.IAVI.ORG X 1996 DE A GLOBAL INITIATIVE FOR SAFE, EFFECTIVE, ACCESSIBLE, PREVENTIVE HIV VACCINES THROUGHOUT THE WORLD. 9 8 163 16 0 0 71447864 63919808 530970 0 -88960 986471 505075 116898 72394949 65023177 19432361 17654908 0 0 23742980 25256275 0 0 2217934 24515090 31036756 67690431 73947939 4704518 -8924762 85094617 89152233 28190268 42089479 56904349 47062754 X INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI) IS A GLOBAL NONPROFIT ORGANIZATION WORKING TO ACCELERATE DEVELOPMENT OF BROADLY EFFECTIVE AIDS VACCINES AND OTHER BIOMEDICAL TOOLS TO PREVENT HIV INFECTION. 0 0 57630380 15762644 RESEARCH AND DEVELOPMENT - WITH A FOCUSED RESEARCH AND DEVELOPMENT AGENDA, IAVI CATALYZES STAKEHOLDERS AROUND THE WORLD TO PROPEL THE SEARCH FOR AN HIV VACCINE. IAVI DESIGNS AND DEVELOPS VACCINE CANDIDATES AND CONDUCTS TRIALS AND RELATED EPIDEMIOLOGICAL RESEARCH IN PARTNERSHIP WITH MORE THAN 50 ACADEMIC, BIOTECHNOLOGY, PHARMACEUTICAL AND GOVERNMENTAL INSTITUTIONS. WITH PIONEERING RESEARCH, IAVI PRIORITIZES TWO SCIENTIFIC APPROACHES: ENGAGING THE IMMUNE SYSTEM TO BLOCK INFECTION, AND TRAINING IT TO RECOGNIZE AND DESTROY CELLS ALREADY INFECTED BY HIV. AS THE FIELD HAS EVOLVED, IAVI IS PREPARED TO CONTRIBUTE TO PREVENTION RESEARCH FOR OTHER INFECTIOUS DISEASES, AND TO INCORPORATE KNOWLEDGE FROM THAT WORK INTO ITS CORE SCIENTIFIC MISSION. HIV VACCINE CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE DEVELOPED 32 HIV VACCINE AND PREVENTION CANDIDATES, ADVANCING 26 INTO EARLY-STAGE CLINICAL TRIALS INCLUDING THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN NATIONS THAT SHOULDER THE GREATEST HIV BURDEN. IAVI HAS CONDUCTED 21 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY TESTING AND COUNSELING TO MORE THAN 500,000 INDIVIDUALS IN AFRICA. IAVI SUBSCRIBES TO THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS FOR CONDUCTING TRIALS, ONE THAT PROTECTS THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO BOOST THE NUMBER AND QUALITY OF NOVEL VACCINE CANDIDATES EVALUATED IN CLINICAL TRIALS AND TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF VACCINE DEVELOPMENT. A SIGNIFICANT PORTION OF THE VACCINE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE 95% OF ALL NEW HIV INFECTIONS OCCUR. 6404913 1892264 VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY - IAVI BELIEVES THAT SUPPORTIVE NATIONAL, REGIONAL, AND GLOBAL POLITICAL, ECONOMIC, AND SOCIETAL ENVIRONMENTS ARE CRITICAL TO THE FASTEST POSSIBLE DEVELOPMENT, APPROVAL, AND DISSEMINATION OF AN AIDS VACCINE. AS A MEMBER OF COALITIONS AND ON ITS OWN, IAVI CONVENES ADVOCATES, POLICYMAKERS, ACTIVISTS, AND REPRESENTATIVES OF THE COMMUNITIES HARDEST HIT BY HVI/AIDS TO RAISE AWARENESS AND STRENGTHEN ADVOCACY CAPACITY AROUND THE WORLD. 64035293 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 X 105 0 1 163 1 0 1 IN KE SF UK 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AR CA CT FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X PATRICK MOUTON 2128471137 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 X ERIC PAUL GOOSBY BOARD CHAIR (AS OF 6/7/16) 2.00 X X 0 0 0 ALEX GODWIN COUTINHO BOARD CHAIR (UNTIL 6/7/16) 2.00 X X 0 0 0 ANNE M VANLENT BOARD VICE CHAIR & TREASURER 2.00 X X 0 0 0 ADEL AF MAHMOUD BOARD MEMBER 1.00 X 0 0 0 FRANCINE NTOUMI BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 MONCEF SLAOUI BOARD MEMBER 1.00 X 0 0 0 PURNIMA MANE BOARD MEMBER 1.00 X 0 0 0 ROBERT GOLDBERG BOARD MEMBER (BEGAN 11/29/16) 1.00 X 0 0 0 MARY C TYDINGS BOARD MEMBER (UNTIL 11/30/16) 1.00 X 0 0 0 THE RT HON THE LORD FOWLER BOARD MEMBER (UNTIL 6/21/16) 1.00 X 0 0 0 ROBIN WEISS SEE SCH O BOARD MEMBER (UNTIL 6/7/16) 1.00 X 10800 0 0 MARK FEINBERG PRESIDENT/CEO 35.00 X X 466174 0 33741 LABEEB ABBOUD SECRETARY/SR VP, GENERAL COUNSEL 35.00 X 354986 0 52467 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 35.00 X 297158 0 52467 ANTHONY MUSYOKA V.P. HUMAN RESOURCES, ASSIT. SECRETARY 35.00 X 286121 0 52467 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 35.00 X 347342 0 52467 CHRISTOPHER PARKS EXEC DIR., VIRAL VACCINES 35.00 X 291557 0 50528 FRANCES PRIDDY EXEC DIR., CHIEF MEDICAL OFFICER 35.00 X 284916 0 29000 DAGNA LAUFER SNR. DIR., MEDICAL AFFAIRS 35.00 X 251275 0 24209 EDDY SAYEED SNR. DIR., PROCESS DEVELOPMENT & MANUFACTURING 35.00 X 235742 0 54642 2826071 0 401988 72 0 1 0 EMMES CORPORATION 401 N WASHINGTON STREET ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 632339 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 587 CRAIGIEBURN VICTORIA AS 3064 REGULATORY CONSULTANT 459147 KEMPER COST MANAGEMENT INC 3300 S LAKESIDE DR OKLAHOMA CITY OK 73179 EQUIPMENT MAINT. SERVICES 303259 VEDDER PRICE PC 8677 SOLUTION CENTER CHICAGO IL 60677 LEGAL SERVICES 281478 CCARL SARL RUE DES PAQUIS 16 1201 GENEVA SZ PROGRAM CONSULTING 148442 7 30192119 33727689 63919808 538881 538881 26614683 20000 26187093 0 427590 20000 447590 447590 MISCELLANEOUS 900099 116898 116898 116898 65023177 0 0 1103369 4651937 4651937 13002971 13002971 1606381 278356 1303029 24996 19011060 14367129 3517432 1126499 1364972 1044218 238795 81959 1981976 1468501 397854 115621 1291886 924809 294318 72759 345088 281478 63610 197930 197930 227000 227000 40741 40741 635635 198551 248668 188416 341226 229118 78834 33274 973530 638321 271429 63780 2855469 2324897 417098 113474 1590416 1303331 227328 59757 835923 685031 119484 31408 1825510 1767012 44894 13604 286967 214063 71185 1719 RESEARCH&CLINICAL SVCS. 17102758 17068276 17979 16503 LAB SUPPLIES/EQUIPMENT 2925616 2925616 EQUIPMENT RENTAL/MAINT. 623270 507461 91041 24768 SUBSCRIPTIONS & PUBS. 143227 96170 33090 13967 86450 58047 19973 8430 73947939 64035293 7694712 2217934 15758074 54335419 25743098 19740832 269058 147338 428326 181545 45752830 36676073 10539665 9076757 31761648 5451968 594748 218374 85094617 89152233 3994765 5320961 4692804 5113044 16101552 27923349 444708 382494 2956439 3349631 28190268 42089479 X 35628942 32402563 21275407 14660191 56904349 47062754 85094617 89152233 X -8924762 -122587 -794246 X 0 1 X 1 1 1 X 59232675 63996178 50593210 71447864 63919808 309189735 59232675 63996178 50593210 71447864 63919808 309189735 66939264 242250471 1772736 1225832 775037 694495 538881 5006981 373183 1030216 587195 505075 116898 2612567 316809283 1042112 0.76470 0.84790 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2012 AMOUNT: $ 41,887. 2013 AMOUNT: $ 209,558. 2014 AMOUNT: $ 70,410. 2015 AMOUNT: $ 146,897. 2016 AMOUNT: $ 54,683. COLLABORATIVE AGREEMENT - 2012 AMOUNT: $ 250,000. 2013 AMOUNT: $ 250,000. 2014 AMOUNT: $ 250,000. WRITE OFF DEFERRED RENT - 2013 AMOUNT: $ 135,063. INNOVATION FUND RETURNED - 2013 AMOUNT: $ 353,000. LOAN FORGIVENESS - 2012 AMOUNT: $ 81,296. 2013 AMOUNT: $ 82,595. 2014 AMOUNT: $ 77,932. 2015 AMOUNT: $ 74,118. 2016 AMOUNT: $ 62,215. WRITE OFF PROVISION FOR RISK - 2014 AMOUNT: $ 188,853. 2015 AMOUNT: $ 284,060. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 227000 227000 73720939 73947939 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 180000 150000 205000 227000 762000 250000 250000 250000 250000 1000000 1500000 19868800 11475716 8393084 25884030 25200357 683673 9076757 DEFERRED RENT PAYABLE 2914126 DEFERRED COMPENSATION PAYABLE 435505 3349631 X 65352356 -122587 234000 1212211 1323624 64028732 40741 953704 994445 65023177 74473040 234000 1285546 1519546 72953494 40741 953704 994445 73947939 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2016, MANAGEMENT OF IAVI HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 959,341. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 252,870. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT 953,704. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 1,198,729. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 86,817. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY EXPENSES, ELIMINATED IN CONSOLIDATED AUDIT 953,704. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EUROPE 1 3 GRANTS TO RECIPIENTS LOCATED IN REGION 4525940 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 317030 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 8160001 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 460497 EUROPE 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2394080 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 46242 SUB-SAHARAN AFRICA 2 20 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2715620 SOUTH ASIA 1 9 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1056607 4 32 0 0 4 32 19676017 0 19676017 EUROPE RESEARCH & DEVELOPMENT 2613401 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1530450 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1312049 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1084635 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1071424 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1047971 WIRE TRANSFER EUROPE VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 953704 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 632344 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 630410 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 527731 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 483675 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 245583 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 196019 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 178367 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 150057 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 134815 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 65923 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 31813 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 23275 WIRE TRANSFER SUB-SAHARAN AFRICA VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 10000 WIRE TRANSFER SUB-SAHARAN AFRICA VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 30030 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 15600 WIRE TRANSFER SUB-SAHARAN AFRICA VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 13999 WIRE TRANSFER SUB-SAHARAN AFRICA VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 12000 WIRE TRANSFER SUB-SAHARAN AFRICA VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 7696 WIRE TRANSFER 23 2 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT WITH A COMPLIANCE OFFICER LOCATED IN EAST AFRICA THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS, ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES ON A REGULAR BASIS. 1 THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 1665195 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 1127891 RESEARCH & DEVELOPMENT AVAC GLOBAL ADVOCACY FOR HIV PREVENTION 423 WEST 127TH STREET 4 FLOOR NEW YORK NY 10027 943240841 501(C)(3) 463279 VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY CHILDREN'S HOSPITAL OF PHILADELPHIA 3535 MARKET STREET 12TH FLOOR PHILADELPHIA PA 19104 231352166 501(C)(3) 353753 RESEARCH & DEVELOPMENT OREGON HEALTH AND SCIENCE UNIVERSITY TTBD FINANCE - L106TT 0690 SW BANCROFT STREET PORTLAND OR 972393098 237083114 501(C)(3) 330681 RESEARCH & DEVELOPMENT UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94158 943067788 501(C)(3) 229327 RESEARCH & DEVELOPMENT NATIONAL INSTITUTE OF ALLERGY-INFECTIOUS DISEASES 6610 ROCKLEDGE DRIVE RM 2800 BETHESDA MD 208926606 530196960 GOVERNMENT 200000 RESEARCH & DEVELOPMENT GLOBAL HIV VACCINE ENTERPRISE 125 BROAD STEET NEW YORK NY 10004 203347314 501(C)(3) 199549 VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY SEATTLE BIOMEDICAL RESEARCH INST DBA CNTR FOR INFECTIONS DISEASE RESEARCH 307 WETLAKE AVE N 500 SEATTLE WA 98109 910961784 501(C)(3) 62630 RESEARCH & DEVELOPMENT UNIVERSITY OF ROCHESTER - INFECTIOUS DISEASES UNIT 601 ELMWOOD AVE BOX 689 ROCHESTER NY 14642 160743209 501(C)(3) 9884 RESEARCH & DEVELOPMENT 10 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT TERMS WHICH INCLUDES SUBSTANTIVE AUDITS, ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES ON A REGULAR BASIS. X X X X X 0 0 0 0 0 0 0 1 0 MARK FEINBERG PRESIDENT/CEO 463984 0 0 0 2190 0 29000 0 4741 0 499915 0 0 0 LABEEB ABBOUD SECRETARY/SR VP, GENERAL COUNSEL 303201 0 32009 0 19776 0 29000 0 23467 0 407453 0 0 0 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 268729 0 26533 0 1896 0 29000 0 23467 0 349625 0 0 0 ANTHONY MUSYOKA V.P. HUMAN RESOURCES, ASSIT. SECRETA 259107 0 25742 0 1272 0 29000 0 23467 0 338588 0 0 0 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 318010 0 27556 0 1776 0 29000 0 23467 0 399809 0 0 0 CHRISTOPHER PARKS EXEC DIR., VIRAL VACCINES 265922 0 23859 0 1776 0 29000 0 21528 0 342085 0 0 0 FRANCES PRIDDY EXEC DIR., CHIEF MEDICAL OFFICER 261821 0 21823 0 1272 0 29000 0 0 0 313916 0 0 0 DAGNA LAUFER SNR. DIR., MEDICAL AFFAIRS 236802 0 12697 0 1776 0 23219 0 990 0 275484 0 0 0 EDDY SAYEED SNR. DIR., PROCESS DEVELOPMENT & MAN 215859 0 18467 0 1416 0 25385 0 29257 0 290384 0 0 0 PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). NOODLE FOX MEDIA THE OWNER OF THE ENTITY IS A FAMILY MEMBER (SPOUSE) OF AN OFFICER OF IAVI. 100384 IAVI HAS A CONSULTING AGREEMENT WITH NOODLE FOX MEDIA, TO PROVIDE MANAGING EDITOR SERVICES FOR IAVI REPORT. THE CONSULTANT WAS SELECTED ON A SOLE SOURCE BASIS, DUE TO UNIQUE SKILL AND EXPERIENCE. THE CONSULTANT HAD PREVIOUSLY SERVED AT IAVI AS MANAGING EDITOR FOR IAVI REPORT, AND BROUGHT RELEVANT SUBSTANTIVE KNOWLEDGE, SCIENTIFIC CONTACTS, AND EXPERTISE IN SCIENCE WRITING, EDITING AND MANAGING THE PUBLICATION PROCESS. THE AGREEMENT WAS ESTABLISHED ON AN ARMS-LENGTH BASIS BY THE ORGANIZATION. 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND FINANCE COMMITTEE REVIEWED AND APPROVED THE FORM 990 IN DETAIL WITH THE CONTROLLER AND CFO. IT WAS THEN SENT TO THE FULL BOARD BEFORE IT WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 ONCE EVERY TWO YEARS, THE COMPENSATION COMMITTEE OF THE BOARD,COMMISSIONS A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. THE SURVEY COMPARES COMPENSATION PACKAGES OF CEO'S OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THE COMMITTEE REVIEWS THE RESULTS OF THE SURVEY AND RECOMMENDATIONS MADE, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI ENGAGES AN EXTERNAL SPECIALIZED FIRM WITH EXPERTISE TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATION COMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN NOVEMBER 2016. IN CONJUNCTION WITH THE CEO'S COMPENSATION REVIEW, THE COMPENSATION COMMITTEE OF THE BOARD ALSO COMMISSIONS AN EXTERNAL COMPARATIVE COMPENSATION SURVEY OF ORGANIZATIONS SIMILAR TO IAVI, IN WHICH THE PACKAGES OF ALL OTHER OFFICERS AND KEY EMPLOYEES ARE BENCHMARKED AGAINST THE LABOR MARKET TO DETERMINE APPROPRIATENESS OF PAY. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THIS SURVEY AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, ONCE EVERY 2 YEARS IAVI COMMISSIONS A COMPENSATION SURVEY, ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. THE RESULTS OF EACH SURVEY ARE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVE MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART VII, SECTION A: BOARD MEMBER ROBIN WEISS WAS PAID FOR CONSULTING SERVICES FOR CHAIRING SCIENTIFIC ADVISORY COMMITTEE. THESE FEES WERE NOT COMPENSATION FOR HIS ROLE ON THE BOARD OF DIRECTORS. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE LOSS -944,246. PROVISION FOR FUTURE FOREIGN EXCHANGE LOSSES 150,000. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE 0 7642042 IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 IAVI HOLDING LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262032322 HOLDING COMPANY DE IAVI INC C 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 IAVI STICHTING B 953704 ACTUAL